May 15, 2024 – The Lancet Infectious Diseases published article on global burden associated with 85 pathogens in 2019. Helicobacter pylori (H. pylori) is the leading pathogen associated with disease burden in China.

This study estimated disability-adjusted life-years (DALYs) associated with 85 pathogens in 2019, globally, regionally, and for 204 countries and territories. Globally, an estimated 704 million DALYs were associated with 85 different pathogens, including 309 million (43·9% of the burden) in children younger than 5 years. This burden accounted for 27·7% (and 65·5% in those younger than 5 years) of the previously reported total DALYs from all causes in 2019. Three leading pathogens responsible for more than 50 million DALYs each in 2019 were tuberculosis (65·1 million), malaria (53·6 million), and HIV or AIDS (52·1 million). Substantial disease burden was associated with previously less recognized pathogens, including Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and H. pylori.

In China, H. pylori was associated with 7.21 million DALYs and was the leading pathogen for disease burden. The second to the fifth pathogens were hepatitis B virus, Staphylococcus aureus, Acinetobacter baumannii and Streptococcus pneumoniae, leading to 6.53 million, 3.76 million, 2.63 million and 2.16 million DALYs in China, respectively.

Link to the article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00158-0/fulltext.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late-stage of clinical development targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com